ZA200810841B - New 1H-indol-1-YL-urea compounds, a process for their preparation and pharmaceutical composiitons containing them - Google Patents
New 1H-indol-1-YL-urea compounds, a process for their preparation and pharmaceutical composiitons containing them Download PDFInfo
- Publication number
- ZA200810841B ZA200810841B ZA200810841A ZA200810841A ZA200810841B ZA 200810841 B ZA200810841 B ZA 200810841B ZA 200810841 A ZA200810841 A ZA 200810841A ZA 200810841 A ZA200810841 A ZA 200810841A ZA 200810841 B ZA200810841 B ZA 200810841B
- Authority
- ZA
- South Africa
- Prior art keywords
- compound
- formula
- indol
- urea
- het
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims description 45
- 238000000034 method Methods 0.000 title claims description 23
- 230000008569 process Effects 0.000 title claims description 19
- KYHGSAOIGRIGQV-UHFFFAOYSA-N indol-1-ylurea Chemical class C1=CC=C2N(NC(=O)N)C=CC2=C1 KYHGSAOIGRIGQV-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims description 77
- -1 2-methylpyridyl Chemical group 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 150000003839 salts Chemical class 0.000 claims description 11
- 239000002253 acid Substances 0.000 claims description 10
- 125000000217 alkyl group Chemical group 0.000 claims description 6
- 230000015572 biosynthetic process Effects 0.000 claims description 6
- 239000012948 isocyanate Substances 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 125000004076 pyridyl group Chemical group 0.000 claims description 6
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 5
- 239000007858 starting material Substances 0.000 claims description 5
- 238000011282 treatment Methods 0.000 claims description 5
- 125000003545 alkoxy group Chemical group 0.000 claims description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
- 125000005936 piperidyl group Chemical group 0.000 claims description 4
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 4
- 238000000926 separation method Methods 0.000 claims description 4
- 230000035882 stress Effects 0.000 claims description 4
- 208000019901 Anxiety disease Diseases 0.000 claims description 3
- 208000018737 Parkinson disease Diseases 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 3
- 230000036506 anxiety Effects 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 231100000252 nontoxic Toxicity 0.000 claims description 3
- 230000003000 nontoxic effect Effects 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
- VOODDYJZNYHVRJ-UHFFFAOYSA-N 1-(2,3-dihydroindol-1-yl)-3-pyridin-3-ylurea Chemical compound C1CC2=CC=CC=C2N1NC(=O)NC1=CC=CN=C1 VOODDYJZNYHVRJ-UHFFFAOYSA-N 0.000 claims description 2
- 208000020401 Depressive disease Diseases 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 230000006978 adaptation Effects 0.000 claims description 2
- 230000032683 aging Effects 0.000 claims description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- 208000035475 disorder Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 229910052736 halogen Inorganic materials 0.000 claims description 2
- 125000005843 halogen group Chemical group 0.000 claims description 2
- 150000002367 halogens Chemical class 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 125000001041 indolyl group Chemical group 0.000 claims description 2
- 230000004770 neurodegeneration Effects 0.000 claims description 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 2
- 238000002638 palliative care Methods 0.000 claims description 2
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 2
- 125000005493 quinolyl group Chemical group 0.000 claims description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims 3
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 claims 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 claims 1
- 238000005979 thermal decomposition reaction Methods 0.000 claims 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 114
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 60
- 239000000243 solution Substances 0.000 description 38
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 36
- 239000000047 product Substances 0.000 description 35
- 238000001914 filtration Methods 0.000 description 32
- 230000008018 melting Effects 0.000 description 28
- 238000002844 melting Methods 0.000 description 28
- 239000011541 reaction mixture Substances 0.000 description 28
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 27
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 24
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 24
- 239000002244 precipitate Substances 0.000 description 24
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 21
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 20
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 18
- 102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 description 18
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 18
- 238000001704 evaporation Methods 0.000 description 16
- 239000002904 solvent Substances 0.000 description 16
- YWEUIGNSBFLMFL-UHFFFAOYSA-N diphosphonate Chemical compound O=P(=O)OP(=O)=O YWEUIGNSBFLMFL-UHFFFAOYSA-N 0.000 description 15
- 239000012074 organic phase Substances 0.000 description 15
- DLYUQMMRRRQYAE-UHFFFAOYSA-N phosphorus pentoxide Inorganic materials O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 14
- 108010007457 Extracellular Signal-Regulated MAP Kinases Proteins 0.000 description 13
- 238000006243 chemical reaction Methods 0.000 description 13
- 238000010992 reflux Methods 0.000 description 13
- 238000003756 stirring Methods 0.000 description 13
- 108091000117 Tyrosine 3-Monooxygenase Proteins 0.000 description 12
- 102000048218 Tyrosine 3-monooxygenases Human genes 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- 229910052786 argon Inorganic materials 0.000 description 10
- 239000007787 solid Substances 0.000 description 10
- 239000004202 carbamide Substances 0.000 description 9
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 9
- 235000019341 magnesium sulphate Nutrition 0.000 description 9
- 230000026731 phosphorylation Effects 0.000 description 9
- 238000006366 phosphorylation reaction Methods 0.000 description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 8
- AMUPGWUVKFXYHG-UHFFFAOYSA-N phenyl n-indol-1-ylcarbamate Chemical compound C1=CC2=CC=CC=C2N1NC(=O)OC1=CC=CC=C1 AMUPGWUVKFXYHG-UHFFFAOYSA-N 0.000 description 8
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 8
- 230000008020 evaporation Effects 0.000 description 7
- VUSYGSNEEYEGGX-UHFFFAOYSA-N indol-1-amine Chemical compound C1=CC=C2N(N)C=CC2=C1 VUSYGSNEEYEGGX-UHFFFAOYSA-N 0.000 description 7
- 238000005406 washing Methods 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 238000003818 flash chromatography Methods 0.000 description 6
- KFUSANSHCADHNJ-UHFFFAOYSA-N pyridine-3-carbohydrazide Chemical compound NNC(=O)C1=CC=CN=C1 KFUSANSHCADHNJ-UHFFFAOYSA-N 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 101000876610 Dictyostelium discoideum Extracellular signal-regulated kinase 2 Proteins 0.000 description 5
- 101001052493 Homo sapiens Mitogen-activated protein kinase 1 Proteins 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 210000004556 brain Anatomy 0.000 description 5
- IIEWJVIFRVWJOD-UHFFFAOYSA-N ethyl cyclohexane Natural products CCC1CCCCC1 IIEWJVIFRVWJOD-UHFFFAOYSA-N 0.000 description 5
- 150000002513 isocyanates Chemical class 0.000 description 5
- 210000000627 locus coeruleus Anatomy 0.000 description 5
- 230000002503 metabolic effect Effects 0.000 description 5
- ICSNLGPSRYBMBD-UHFFFAOYSA-N 2-aminopyridine Chemical compound NC1=CC=CC=N1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 description 4
- RAQJUUBNJUGZGQ-UHFFFAOYSA-N 5-chloroindol-1-amine Chemical compound ClC1=CC=C2N(N)C=CC2=C1 RAQJUUBNJUGZGQ-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 108040008097 MAP kinase activity proteins Proteins 0.000 description 4
- 102000019149 MAP kinase activity proteins Human genes 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 239000012298 atmosphere Substances 0.000 description 4
- 230000008499 blood brain barrier function Effects 0.000 description 4
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 4
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- JBFYUZGYRGXSFL-UHFFFAOYSA-N imidazolide Chemical compound C1=C[N-]C=N1 JBFYUZGYRGXSFL-UHFFFAOYSA-N 0.000 description 4
- 239000000543 intermediate Substances 0.000 description 4
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 4
- BZLAZAYSIDERLU-UHFFFAOYSA-N 1-indol-1-yl-3-pyridin-3-ylurea Chemical compound C1=CC2=CC=CC=C2N1NC(=O)NC1=CC=CN=C1 BZLAZAYSIDERLU-UHFFFAOYSA-N 0.000 description 3
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229960000583 acetic acid Drugs 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000012047 saturated solution Substances 0.000 description 3
- 201000000980 schizophrenia Diseases 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 2
- IHWDSEPNZDYMNF-UHFFFAOYSA-N 1H-indol-2-amine Chemical compound C1=CC=C2NC(N)=CC2=C1 IHWDSEPNZDYMNF-UHFFFAOYSA-N 0.000 description 2
- WLFGGJFWKXTOGJ-UHFFFAOYSA-N 2,3-dihydroindol-1-amine Chemical compound C1=CC=C2N(N)CCC2=C1 WLFGGJFWKXTOGJ-UHFFFAOYSA-N 0.000 description 2
- CUYKNJBYIJFRCU-UHFFFAOYSA-N 3-aminopyridine Chemical compound NC1=CC=CN=C1 CUYKNJBYIJFRCU-UHFFFAOYSA-N 0.000 description 2
- SHVVSKCXWMEDRW-UHFFFAOYSA-N 3-isocyanatopyridine Chemical compound O=C=NC1=CC=CN=C1 SHVVSKCXWMEDRW-UHFFFAOYSA-N 0.000 description 2
- FVGKWRLEJUDITN-UHFFFAOYSA-N 5-methoxy-2,3-dihydroindol-1-amine Chemical compound COC1=CC=C2N(N)CCC2=C1 FVGKWRLEJUDITN-UHFFFAOYSA-N 0.000 description 2
- FQTGEHXJENVUAA-UHFFFAOYSA-N 5-methoxyindol-1-amine Chemical compound COC1=CC=C2N(N)C=CC2=C1 FQTGEHXJENVUAA-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- ACFIXJIJDZMPPO-NNYOXOHSSA-N NADPH Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](OP(O)(O)=O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 ACFIXJIJDZMPPO-NNYOXOHSSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 150000008064 anhydrides Chemical class 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 229960003638 dopamine Drugs 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- YDNLNVZZTACNJX-UHFFFAOYSA-N isocyanatomethylbenzene Chemical compound O=C=NCC1=CC=CC=C1 YDNLNVZZTACNJX-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 210000001589 microsome Anatomy 0.000 description 2
- NGQGJPOFMNUUMN-UHFFFAOYSA-N n-indol-1-ylimidazole-1-carboxamide Chemical compound C1=CC2=CC=CC=C2N1NC(=O)N1C=CN=C1 NGQGJPOFMNUUMN-UHFFFAOYSA-N 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 2
- 229960002748 norepinephrine Drugs 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- AHWALFGBDFAJAI-UHFFFAOYSA-N phenyl carbonochloridate Chemical compound ClC(=O)OC1=CC=CC=C1 AHWALFGBDFAJAI-UHFFFAOYSA-N 0.000 description 2
- DGTNSSLYPYDJGL-UHFFFAOYSA-N phenyl isocyanate Chemical compound O=C=NC1=CC=CC=C1 DGTNSSLYPYDJGL-UHFFFAOYSA-N 0.000 description 2
- MIHNYWUSIIHCFG-UHFFFAOYSA-N phenyl n-indol-1-yl-n-methylcarbamate Chemical compound C1=CC2=CC=CC=C2N1N(C)C(=O)OC1=CC=CC=C1 MIHNYWUSIIHCFG-UHFFFAOYSA-N 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 210000002442 prefrontal cortex Anatomy 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- 235000010288 sodium nitrite Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- RUEMLKUMKKDJTF-UHFFFAOYSA-N (2z)-n-diazoniopyridine-2-carboximidate Chemical compound [N-]=[N+]=NC(=O)C1=CC=CC=N1 RUEMLKUMKKDJTF-UHFFFAOYSA-N 0.000 description 1
- PVINVALGNQGHPB-UHFFFAOYSA-N 1,3-bis(5-chloroindol-1-yl)urea Chemical compound C1=CC2=CC(Cl)=CC=C2N1NC(=O)NN1C2=CC=C(Cl)C=C2C=C1 PVINVALGNQGHPB-UHFFFAOYSA-N 0.000 description 1
- CVGKOAUAZFTHMZ-UHFFFAOYSA-N 1,3-di(indol-1-yl)urea Chemical compound C1=CC2=CC=CC=C2N1NC(=O)NN1C2=CC=CC=C2C=C1 CVGKOAUAZFTHMZ-UHFFFAOYSA-N 0.000 description 1
- ZKJVUUBRGVDXRO-UHFFFAOYSA-N 1-(2,3-dihydroindol-1-yl)-3-(1-methylpiperidin-3-yl)urea Chemical compound C1N(C)CCCC1NC(=O)NN1C2=CC=CC=C2CC1 ZKJVUUBRGVDXRO-UHFFFAOYSA-N 0.000 description 1
- CXPLUWMTGHGVBC-UHFFFAOYSA-N 1-(2,3-dihydroindol-1-yl)-3-pyridin-2-ylurea Chemical compound C1CC2=CC=CC=C2N1NC(=O)NC1=CC=CC=N1 CXPLUWMTGHGVBC-UHFFFAOYSA-N 0.000 description 1
- IZQDVYYMDFJBJM-UHFFFAOYSA-N 1-(5-chloro-2,3-dihydroindol-1-yl)-3-pyridin-3-ylurea Chemical compound C1CC2=CC(Cl)=CC=C2N1NC(=O)NC1=CC=CN=C1 IZQDVYYMDFJBJM-UHFFFAOYSA-N 0.000 description 1
- FGQUQHPDIIOGFM-UHFFFAOYSA-N 1-(5-chloroindol-1-yl)-3-phenylurea Chemical compound C1=CC2=CC(Cl)=CC=C2N1NC(=O)NC1=CC=CC=C1 FGQUQHPDIIOGFM-UHFFFAOYSA-N 0.000 description 1
- QYYWWFLOQMZOLW-UHFFFAOYSA-N 1-(5-chloroindol-1-yl)-3-pyridin-2-ylurea Chemical compound C1=CC2=CC(Cl)=CC=C2N1NC(=O)NC1=CC=CC=N1 QYYWWFLOQMZOLW-UHFFFAOYSA-N 0.000 description 1
- HJUSXNFZRBJHDM-UHFFFAOYSA-N 1-(5-chloroindol-1-yl)-3-pyridin-4-ylurea Chemical compound C1=CC2=CC(Cl)=CC=C2N1NC(=O)NC1=CC=NC=C1 HJUSXNFZRBJHDM-UHFFFAOYSA-N 0.000 description 1
- BWCPPUQNLRMJMU-UHFFFAOYSA-N 1-(5-methoxy-2,3-dihydroindol-1-yl)-3-pyridin-3-ylurea Chemical compound C1CC2=CC(OC)=CC=C2N1NC(=O)NC1=CC=CN=C1 BWCPPUQNLRMJMU-UHFFFAOYSA-N 0.000 description 1
- HDLFXTXHFYCSAF-UHFFFAOYSA-N 1-(5-methoxyindol-1-yl)-3-pyridin-3-ylurea Chemical compound C1=CC2=CC(OC)=CC=C2N1NC(=O)NC1=CC=CN=C1 HDLFXTXHFYCSAF-UHFFFAOYSA-N 0.000 description 1
- PNVMGVGMBQBIBR-UHFFFAOYSA-N 1-(5-methylindol-1-yl)-3-pyridin-3-ylurea Chemical compound C1=CC2=CC(C)=CC=C2N1NC(=O)NC1=CC=CN=C1 PNVMGVGMBQBIBR-UHFFFAOYSA-N 0.000 description 1
- KBMFHESQPMHPMN-UHFFFAOYSA-N 1-(6-chloropyridazin-3-yl)-3-indol-1-ylurea Chemical compound N1=NC(Cl)=CC=C1NC(=O)NN1C2=CC=CC=C2C=C1 KBMFHESQPMHPMN-UHFFFAOYSA-N 0.000 description 1
- VJMSSHQXPWFEQA-UHFFFAOYSA-N 1-benzyl-3-(5-chloroindol-1-yl)urea Chemical compound C1=CC2=CC(Cl)=CC=C2N1NC(=O)NCC1=CC=CC=C1 VJMSSHQXPWFEQA-UHFFFAOYSA-N 0.000 description 1
- XDQQXTIJUAJOGJ-UHFFFAOYSA-N 1-benzyl-3-indol-1-ylurea Chemical compound C1=CC2=CC=CC=C2N1NC(=O)NCC1=CC=CC=C1 XDQQXTIJUAJOGJ-UHFFFAOYSA-N 0.000 description 1
- FHUYWGUVVZSTNX-UHFFFAOYSA-N 1-indol-1-yl-1,3-dimethyl-3-pyridin-3-ylurea Chemical compound C1=CC2=CC=CC=C2N1N(C)C(=O)N(C)C1=CC=CN=C1 FHUYWGUVVZSTNX-UHFFFAOYSA-N 0.000 description 1
- NDNOQKRZONXDJI-UHFFFAOYSA-N 1-indol-1-yl-1-methyl-3-pyridin-3-ylurea Chemical compound C1=CC2=CC=CC=C2N1N(C)C(=O)NC1=CC=CN=C1 NDNOQKRZONXDJI-UHFFFAOYSA-N 0.000 description 1
- WKPYZOVTAWBXLU-UHFFFAOYSA-N 1-indol-1-yl-3-(1-methylpiperidin-2-yl)urea Chemical compound CN1CCCCC1NC(=O)NN1C2=CC=CC=C2C=C1 WKPYZOVTAWBXLU-UHFFFAOYSA-N 0.000 description 1
- SIVFCDHJOONHLS-UHFFFAOYSA-N 1-indol-1-yl-3-(1-methylpiperidin-3-yl)urea Chemical compound C1N(C)CCCC1NC(=O)NN1C2=CC=CC=C2C=C1 SIVFCDHJOONHLS-UHFFFAOYSA-N 0.000 description 1
- AHCITOLZKNTRTG-UHFFFAOYSA-N 1-indol-1-yl-3-(1h-pyridazin-2-yl)urea Chemical compound C1=CC2=CC=CC=C2N1NC(=O)NN1NC=CC=C1 AHCITOLZKNTRTG-UHFFFAOYSA-N 0.000 description 1
- ADBKMWFLHRUPDA-UHFFFAOYSA-N 1-indol-1-yl-3-(pyridin-2-ylmethyl)urea Chemical compound C1=CC2=CC=CC=C2N1NC(=O)NCC1=CC=CC=N1 ADBKMWFLHRUPDA-UHFFFAOYSA-N 0.000 description 1
- BLMKHZIXGWUZES-UHFFFAOYSA-N 1-indol-1-yl-3-(pyridin-3-ylmethyl)urea Chemical compound C1=CC2=CC=CC=C2N1NC(=O)NCC1=CC=CN=C1 BLMKHZIXGWUZES-UHFFFAOYSA-N 0.000 description 1
- FQQXDUWVZQDBNI-UHFFFAOYSA-N 1-indol-1-yl-3-(pyridin-4-ylmethyl)urea Chemical compound C1=CC2=CC=CC=C2N1NC(=O)NCC1=CC=NC=C1 FQQXDUWVZQDBNI-UHFFFAOYSA-N 0.000 description 1
- ZAGRRMHLQLQBIW-UHFFFAOYSA-N 1-indol-1-yl-3-phenylurea Chemical compound C1=CC2=CC=CC=C2N1NC(=O)NC1=CC=CC=C1 ZAGRRMHLQLQBIW-UHFFFAOYSA-N 0.000 description 1
- PAHILJJIWVPHHB-UHFFFAOYSA-N 1-indol-1-yl-3-pyridin-2-ylurea Chemical compound C1=CC2=CC=CC=C2N1NC(=O)NC1=CC=CC=N1 PAHILJJIWVPHHB-UHFFFAOYSA-N 0.000 description 1
- IZCMRNLRLYJGRT-UHFFFAOYSA-N 1-indol-1-yl-3-pyridin-4-ylurea Chemical compound C1=CC2=CC=CC=C2N1NC(=O)NC1=CC=NC=C1 IZCMRNLRLYJGRT-UHFFFAOYSA-N 0.000 description 1
- WUGIJBNNJDPRCV-UHFFFAOYSA-N 1-indol-1-yl-3-pyrimidin-2-ylurea Chemical compound C1=CC2=CC=CC=C2N1NC(=O)NC1=NC=CC=N1 WUGIJBNNJDPRCV-UHFFFAOYSA-N 0.000 description 1
- CGPVBYCADKUNOU-UHFFFAOYSA-N 1-indol-1-yl-3-quinolin-3-ylurea Chemical compound C1=CC2=CC=CC=C2N1NC(=O)NC1=CN=C(C=CC=C2)C2=C1 CGPVBYCADKUNOU-UHFFFAOYSA-N 0.000 description 1
- CPNBTHXFTHHXEX-UHFFFAOYSA-N 1-indol-1-yl-3-quinolin-5-ylurea Chemical compound C1=CC2=CC=CC=C2N1NC(=O)NC1=CC=CC2=NC=CC=C12 CPNBTHXFTHHXEX-UHFFFAOYSA-N 0.000 description 1
- KECYCDLZPXESBS-UHFFFAOYSA-N 1-indol-1-yl-3-quinolin-6-ylurea Chemical compound C1=CC2=CC=CC=C2N1NC(=O)NC1=CC=C(N=CC=C2)C2=C1 KECYCDLZPXESBS-UHFFFAOYSA-N 0.000 description 1
- GJKVJLIXLUFOCQ-UHFFFAOYSA-N 1-indol-1-yl-3-quinolin-8-ylurea Chemical compound C1=CC2=CC=CC=C2N1NC(=O)NC1=CC=CC2=CC=CN=C12 GJKVJLIXLUFOCQ-UHFFFAOYSA-N 0.000 description 1
- QLLYMFDMNMDIDN-UHFFFAOYSA-N 1-methylpiperidine-3-carbonyl azide Chemical compound CN1CCCC(C(=O)N=[N+]=[N-])C1 QLLYMFDMNMDIDN-UHFFFAOYSA-N 0.000 description 1
- SENQSZAIVIKICV-UHFFFAOYSA-N 1-methylpiperidine-4-carbonyl azide Chemical compound CN1CCC(C(=O)N=[N+]=[N-])CC1 SENQSZAIVIKICV-UHFFFAOYSA-N 0.000 description 1
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 1
- ZFYUCIPARAFUGP-UHFFFAOYSA-N 1h-pyridazin-2-amine Chemical compound NN1NC=CC=C1 ZFYUCIPARAFUGP-UHFFFAOYSA-N 0.000 description 1
- DTXVKPOKPFWSFF-UHFFFAOYSA-N 3(S)-hydroxy-13-cis-eicosenoyl-CoA Chemical compound NC1=CC=C(Cl)N=N1 DTXVKPOKPFWSFF-UHFFFAOYSA-N 0.000 description 1
- SVNCRRZKBNSMIV-UHFFFAOYSA-N 3-Aminoquinoline Chemical compound C1=CC=CC2=CC(N)=CN=C21 SVNCRRZKBNSMIV-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- VZIXEZYLLCSREF-UHFFFAOYSA-N 3-indol-1-yl-1-methyl-1-pyridin-3-ylurea Chemical compound C1=CC2=CC=CC=C2N1NC(=O)N(C)C1=CC=CN=C1 VZIXEZYLLCSREF-UHFFFAOYSA-N 0.000 description 1
- WUTIWOZYHHSBBU-UHFFFAOYSA-N 3-methoxy-4-nitrobenzaldehyde Chemical compound COC1=CC(C=O)=CC=C1[N+]([O-])=O WUTIWOZYHHSBBU-UHFFFAOYSA-N 0.000 description 1
- PHSCZLWBNAKWML-UHFFFAOYSA-N 5-chloro-2,3-dihydroindol-1-amine Chemical compound ClC1=CC=C2N(N)CCC2=C1 PHSCZLWBNAKWML-UHFFFAOYSA-N 0.000 description 1
- YQKGINYGQKVPEQ-UHFFFAOYSA-N 5-methoxy-1-nitroso-2,3-dihydroindole Chemical compound COC1=CC=C2N(N=O)CCC2=C1 YQKGINYGQKVPEQ-UHFFFAOYSA-N 0.000 description 1
- YYDYAQAVAHKFJO-UHFFFAOYSA-N 5-methoxy-2,3-dihydro-1h-indole Chemical compound COC1=CC=C2NCCC2=C1 YYDYAQAVAHKFJO-UHFFFAOYSA-N 0.000 description 1
- DWAQDRSOVMLGRQ-UHFFFAOYSA-N 5-methoxyindole Chemical compound COC1=CC=C2NC=CC2=C1 DWAQDRSOVMLGRQ-UHFFFAOYSA-N 0.000 description 1
- FCSRGPYSAUCMJN-UHFFFAOYSA-N 5-methylindol-1-amine Chemical compound CC1=CC=C2N(N)C=CC2=C1 FCSRGPYSAUCMJN-UHFFFAOYSA-N 0.000 description 1
- WREVVZMUNPAPOV-UHFFFAOYSA-N 8-aminoquinoline Chemical compound C1=CN=C2C(N)=CC=CC2=C1 WREVVZMUNPAPOV-UHFFFAOYSA-N 0.000 description 1
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101100372662 Caenorhabditis elegans vem-1 gene Proteins 0.000 description 1
- LSPHULWDVZXLIL-UHFFFAOYSA-N Camphoric acid Natural products CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical group NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 1
- OPFTUNCRGUEPRZ-QLFBSQMISA-N Cyclohexane Natural products CC(=C)[C@@H]1CC[C@@](C)(C=C)[C@H](C(C)=C)C1 OPFTUNCRGUEPRZ-QLFBSQMISA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 208000009668 Neurobehavioral Manifestations Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 235000012501 ammonium carbonate Nutrition 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 230000005978 brain dysfunction Effects 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- LSPHULWDVZXLIL-QUBYGPBYSA-N camphoric acid Chemical compound CC1(C)[C@H](C(O)=O)CC[C@]1(C)C(O)=O LSPHULWDVZXLIL-QUBYGPBYSA-N 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000000768 catecholaminergic effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- AGKGVUYGXIXJPZ-UHFFFAOYSA-N cyclohexanecarboxamide;1h-indole Chemical class C1=CC=C2NC=CC2=C1.NC(=O)C1CCCCC1 AGKGVUYGXIXJPZ-UHFFFAOYSA-N 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007357 depressive behavior Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 210000005064 dopaminergic neuron Anatomy 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 150000002475 indoles Chemical class 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000006386 memory function Effects 0.000 description 1
- NNRDTRXBVBOCAG-UHFFFAOYSA-N n,n-dimethylpyridin-4-amine;hydrochloride Chemical compound Cl.CN(C)C1=CC=NC=C1 NNRDTRXBVBOCAG-UHFFFAOYSA-N 0.000 description 1
- SVEUVITYHIHZQE-UHFFFAOYSA-N n-methylpyridin-2-amine Chemical compound CNC1=CC=CC=N1 SVEUVITYHIHZQE-UHFFFAOYSA-N 0.000 description 1
- DBGFNLVRAFYZBI-UHFFFAOYSA-N n-methylpyridin-3-amine Chemical compound CNC1=CC=CN=C1 DBGFNLVRAFYZBI-UHFFFAOYSA-N 0.000 description 1
- 210000001577 neostriatum Anatomy 0.000 description 1
- 230000007996 neuronal plasticity Effects 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 1
- 229950010883 phencyclidine Drugs 0.000 description 1
- JQFIWELAGHWNIN-UHFFFAOYSA-N phenyl n-quinolin-3-ylcarbamate Chemical compound C=1N=C2C=CC=CC2=CC=1NC(=O)OC1=CC=CC=C1 JQFIWELAGHWNIN-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- HDOUGSFASVGDCS-UHFFFAOYSA-N pyridin-3-ylmethanamine Chemical compound NCC1=CC=CN=C1 HDOUGSFASVGDCS-UHFFFAOYSA-N 0.000 description 1
- TXQWFIVRZNOPCK-UHFFFAOYSA-N pyridin-4-ylmethanamine Chemical compound NCC1=CC=NC=C1 TXQWFIVRZNOPCK-UHFFFAOYSA-N 0.000 description 1
- VYMROWZUHYKURR-UHFFFAOYSA-N pyridine-4-carbonyl azide Chemical compound [N-]=[N+]=NC(=O)C1=CC=NC=C1 VYMROWZUHYKURR-UHFFFAOYSA-N 0.000 description 1
- LJXQPZWIHJMPQQ-UHFFFAOYSA-N pyrimidin-2-amine Chemical compound NC1=NC=CC=N1 LJXQPZWIHJMPQQ-UHFFFAOYSA-N 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- XMIAFAKRAAMSGX-UHFFFAOYSA-N quinolin-5-amine Chemical compound C1=CC=C2C(N)=CC=CC2=N1 XMIAFAKRAAMSGX-UHFFFAOYSA-N 0.000 description 1
- RJSRSRITMWVIQT-UHFFFAOYSA-N quinolin-6-amine Chemical compound N1=CC=CC2=CC(N)=CC=C21 RJSRSRITMWVIQT-UHFFFAOYSA-N 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 150000003385 sodium Chemical class 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 239000006190 sub-lingual tablet Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000003956 synaptic plasticity Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000004885 tandem mass spectrometry Methods 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- JLTRXTDYQLMHGR-UHFFFAOYSA-N trimethylaluminium Chemical compound C[Al](C)C JLTRXTDYQLMHGR-UHFFFAOYSA-N 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0800043A FR2926077A1 (fr) | 2008-01-04 | 2008-01-04 | Nouveaux derives d'1h-indol-1-yl uree, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200810841B true ZA200810841B (en) | 2009-12-30 |
Family
ID=39427563
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200810841A ZA200810841B (en) | 2008-01-04 | 2008-12-23 | New 1H-indol-1-YL-urea compounds, a process for their preparation and pharmaceutical composiitons containing them |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20090176794A1 (pt) |
| EP (1) | EP2078716A1 (pt) |
| JP (1) | JP2009196976A (pt) |
| KR (1) | KR20090075632A (pt) |
| CN (1) | CN101475560A (pt) |
| AR (1) | AR070070A1 (pt) |
| AU (1) | AU2009200010A1 (pt) |
| BR (1) | BRPI0900030A2 (pt) |
| CA (1) | CA2648836A1 (pt) |
| EA (1) | EA200802427A1 (pt) |
| FR (1) | FR2926077A1 (pt) |
| MA (1) | MA30619B1 (pt) |
| MX (1) | MX2009000254A (pt) |
| NZ (1) | NZ573976A (pt) |
| SG (1) | SG153774A1 (pt) |
| WO (1) | WO2009106753A1 (pt) |
| ZA (1) | ZA200810841B (pt) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11446268B2 (en) * | 2019-02-01 | 2022-09-20 | Yamo Pharmaceuticals Llc | Compositions and methods for treating anxiety-related disorders |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3454583A (en) | 1965-07-19 | 1969-07-08 | Us Health Education & Welfare | Synthesis of vincamine |
| FR2381048A1 (fr) | 1977-02-22 | 1978-09-15 | Roussel Uclaf | Nouveaux derives de 20,21-dinoreburnamenine, un procede pour leur preparation et leur application comme medicaments |
| FR2433528A2 (fr) | 1978-08-16 | 1980-03-14 | Roussel Uclaf | Nouveaux derives de 20,21-dinoreburnamenine, un procede pour leur preparation et leur application comme medicaments |
| FR2614022B1 (fr) | 1987-04-15 | 1989-12-01 | Roussel Uclaf | Nouveaux derives 17-aza de 20,21-dinoreburnamenine, leur procede de preparation et les nouveaux intermediaires ainsi obtenus, leur application comme medicaments et ces compositions les renfermant |
| WO1993018026A1 (en) * | 1992-03-04 | 1993-09-16 | Beecham Group Plc | Indole ureas as 5-ht1c receptor antogonists |
| US5319096A (en) * | 1992-04-03 | 1994-06-07 | Hoechst-Roussel Pharmaceuticals Inc. | (1H-indol-1-yl)-2-(amino) acetamides and related (1H-indol-1-yl)-(aminoalkyl)amides, pharmaceutical composition and use |
| FR2713644B1 (fr) | 1993-12-14 | 1996-02-09 | Adir | Nouveaux analogues de l'éburnane, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent. |
| AUPO390996A0 (en) * | 1996-11-29 | 1996-12-19 | Fujisawa Pharmaceutical Co., Ltd. | Urea derivatives |
| FR2888238B1 (fr) * | 2005-07-07 | 2007-09-07 | Servier Lab | Nouveaux derives 1h-indole-pyridinecarboxamides et 1h-indole-piperidinecarboxamide, leur procede de preparation et les compositions pharceumatiques qui les contiennent. |
| FR2911143A1 (fr) * | 2007-01-05 | 2008-07-11 | Servier Lab | Utilisation de composes neuroprotecteurs pour l'obtention de medicaments destines au traitement de maladies neurodegeneratives. |
-
2008
- 2008-01-04 FR FR0800043A patent/FR2926077A1/fr active Pending
- 2008-12-18 SG SG200809399-9A patent/SG153774A1/en unknown
- 2008-12-23 ZA ZA200810841A patent/ZA200810841B/en unknown
- 2008-12-24 NZ NZ573976A patent/NZ573976A/en not_active IP Right Cessation
- 2008-12-26 JP JP2008331704A patent/JP2009196976A/ja active Pending
- 2008-12-26 MA MA31520A patent/MA30619B1/fr unknown
- 2008-12-29 EA EA200802427A patent/EA200802427A1/ru unknown
- 2008-12-30 AR ARP080105775A patent/AR070070A1/es unknown
- 2008-12-30 CN CNA2008101905458A patent/CN101475560A/zh active Pending
- 2008-12-30 US US12/317,904 patent/US20090176794A1/en not_active Abandoned
- 2008-12-31 CA CA002648836A patent/CA2648836A1/fr not_active Abandoned
- 2008-12-31 WO PCT/FR2008/001842 patent/WO2009106753A1/fr active Application Filing
- 2008-12-31 EP EP08291259A patent/EP2078716A1/fr not_active Withdrawn
-
2009
- 2009-01-02 BR BRPI0900030-5A patent/BRPI0900030A2/pt not_active IP Right Cessation
- 2009-01-02 KR KR1020090000077A patent/KR20090075632A/ko not_active Application Discontinuation
- 2009-01-02 AU AU2009200010A patent/AU2009200010A1/en not_active Abandoned
- 2009-01-07 MX MX2009000254A patent/MX2009000254A/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| US20090176794A1 (en) | 2009-07-09 |
| WO2009106753A1 (fr) | 2009-09-03 |
| NZ573976A (en) | 2010-05-28 |
| FR2926077A1 (fr) | 2009-07-10 |
| MX2009000254A (es) | 2009-08-12 |
| BRPI0900030A2 (pt) | 2009-09-15 |
| CA2648836A1 (fr) | 2009-07-04 |
| SG153774A1 (en) | 2009-07-29 |
| KR20090075632A (ko) | 2009-07-08 |
| AU2009200010A1 (en) | 2009-07-23 |
| MA30619B1 (fr) | 2009-08-03 |
| EA200802427A1 (ru) | 2009-06-30 |
| AR070070A1 (es) | 2010-03-10 |
| EP2078716A1 (fr) | 2009-07-15 |
| CN101475560A (zh) | 2009-07-08 |
| JP2009196976A (ja) | 2009-09-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6962941B2 (ja) | Ａｐｊ受容体アゴニストとしての４−ヒドロキシ−３−スルホニルピリジン−２（１ｈ）−オン | |
| JP6987792B2 (ja) | Ｒｏｃｋ阻害剤としてのトリアゾロンおよびテトラゾロン | |
| JP2016510032A (ja) | 強力なｒｏｃｋ１およびｒｏｃｋ２阻害剤としてのフェニルピラゾール誘導体 | |
| CN105518005A (zh) | 作为rock抑制剂的三环吡啶-甲酰胺衍生物 | |
| JP2016510033A (ja) | 強力なｒｏｃｋ１およびｒｏｃｋ２阻害剤としてのフェニルピラゾール誘導体 | |
| JP2010522719A (ja) | プリニル誘導体及びカリウムチャネルモジュレーターとしてのそれらの使用 | |
| NZ243783A (en) | 5-aminosulphonylisoquinoline derivatives and pharmaceutical compositions | |
| CN102317289A (zh) | 作为β分泌酶抑制剂的内酰胺 | |
| JP2011506333A (ja) | 新規ｓＥＨ阻害剤およびその使用 | |
| JP2009506127A (ja) | 糖尿病の処置に有用なアニリノピラゾール誘導体 | |
| CN109153672B (zh) | Trpv4拮抗剂 | |
| NZ334201A (en) | Bisindolylmaleimide derivative linked via an indolyl nitrogen to an alkyl terminated with an aryl or heteroaryl | |
| TW201902887A (zh) | 做為血漿激肽釋放酶抑制劑之雜芳基甲醯胺衍生物 | |
| AU2009259121B2 (en) | Novel derivatives of (bridged piperazinyl)-1-alkanone and use thereof as p75 inhibitors | |
| JPH06211838A (ja) | ピペリジン誘導体、その製造法および治療への応用 | |
| JP2011510998A (ja) | 新規ｓＥＨ阻害剤およびその使用 | |
| ZA200810841B (en) | New 1H-indol-1-YL-urea compounds, a process for their preparation and pharmaceutical composiitons containing them | |
| JP2016505584A (ja) | ダウン症候群及びアルツハイマー病に関連する認知欠損の治療のための、ｄｙｒｋ１ａタンパク質阻害剤としての３，５−ジアリールアザインドール類 | |
| US5410057A (en) | 1-heteroarylazetidines and -pyrrolidines | |
| EP1874777B1 (fr) | Dérivés de 1h-pyrimido[4,5-b]indole, leur préparation et leur application en thérapeutique | |
| EP1458721B1 (fr) | Derives de 3-heteroaryl-3,5-dihydro-4-oxo-4h-pyridazino [4,5-b] indole-1-carboxamide, leur preparation et leur application en therapeutique | |
| HU195214B (en) | Process for producing 12b-substituted-1-(hydroxymethyl)-octahydro-indolo /2,3-a/ quinolizine derivatives and pharmaceutical preparations comprising these compounds | |
| US5047402A (en) | Cyclic amides as medicaments | |
| JPH107658A (ja) | スルホニルウレイドピラゾール誘導体 | |
| EA043363B1 (ru) | Ингибиторы rho-ассоциированной суперспираль содержащей протеинкиназы |